{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:07:56Z","timestamp":1791958076244,"version":"4.3.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Proton pump inhibitors (PPIs) are increasingly used during pregnancy; however, several observational studies have raised concerns about an increased risk of specific types of congenital malformations.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the association between PPI exposure during early pregnancy and the risk of congenital malformations.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study used data from the National Health Insurance Service\u2013National Health Information Database of South Korea (2010-2020); sibling-controlled analyses were conducted to account for familial factors. A total of 2 696 216 pregnancies in women aged 19 to 44 years between June 1, 2011, and December 31, 2019, and their live-born infants were identified. Pregnant women who were exposed to known teratogens or who delivered infants with chromosomal abnormalities or genetic syndromes were excluded. Data on participant race and ethnicity were not collected because the National Health Information Database does not report this information.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Proton pump inhibitor use during the first trimester.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were major congenital malformations, congenital heart defects, cleft palate, hydrocephalus, and hypospadias. The subtypes of major congenital malformations and congenital heart defects were evaluated as exploratory outcomes. Propensity score fine stratification was used to control for potential confounders, and a weighted generalized linear model was used to estimate relative risks with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2\u202f696\u202f216 pregnancies (mean [SD] maternal age, 32.1 [4.2] years), 40\u202f540 (1.5%; mean [SD] age, 32.4 [4.6] years) were exposed to PPIs during the first trimester. The absolute risk of major congenital malformations was 396.7 per 10\u202f000 infants in PPI-exposed pregnancies and 323.4 per 10\u202f000 infants in unexposed pregnancies. The propensity score\u2013adjusted relative risks were 1.07 (95% CI, 1.02-1.13) for major congenital malformations, 1.09 (95% CI, 1.01-1.17) for congenital heart defects, 1.02 (95% CI, 0.72-1.43) for cleft palate, 0.94 (95% CI, 0.54-1.63) for hydrocephalus, and 0.77 (95% CI, 0.51-1.17) for hypospadias. In the sibling-controlled analyses, no associations were observed between PPI use and primary outcomes, including major congenital malformations (odds ratio, 1.05; 95% CI, 0.91-1.22) and congenital heart defects (odds ratio, 1.07; 95% CI, 0.88-1.30). A range of sensitivity analyses revealed results that were similar to the main findings.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, the use of PPIs during early pregnancy was not associated with a substantial increase in the risk of congenital malformations, although small increased risks were observed for major congenital malformations and congenital heart defects; findings from sibling-controlled analyses revealed that PPIs were unlikely to be major teratogens. These findings may help guide clinicians and patients in decision-making about PPI use in the first trimester.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.50366","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T11:08:00Z","timestamp":1673348880000},"page":"e2250366","source":"Crossref","is-referenced-by-count":29,"title":["Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations"],"prefix":"10.1001","volume":"6","author":[{"given":"Ahhyung","family":"Choi","sequence":"first","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunha","family":"Noh","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Eol","family":"Jeong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Choi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, University College London School of Pharmacy, London, United Kingdom"},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yeol","family":"Han","sequence":"additional","affiliation":[{"name":"Korean Mothersafe Counselling Center, Department of Obstetrics and Gynecology, Inje University Ilsan Paik Hospital, Goyang, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"5","key":"zoi221425r1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bpg.2007.05.006","article-title":"Gastroesophageal reflux disease in pregnancy.","volume":"21","author":"Ali","year":"2007","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"zoi221425r2","doi-asserted-by":"publisher","author":"Meyer","year":"2021","DOI":"10.1371\/journal.pone.0245854"},{"key":"zoi221425r3","doi-asserted-by":"publisher","author":"Strand","year":"2017","DOI":"10.5009\/gnl15502"},{"issue":"7","key":"zoi221425r4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1023\/A:1015863018105","article-title":"Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.","volume":"47","author":"Nikfar","year":"2002","journal-title":"Dig Dis Sci"},{"key":"zoi221425r5","doi-asserted-by":"publisher","author":"Gill","year":"2009","DOI":"10.1038\/ajg.2009.122"},{"issue":"22","key":"zoi221425r6","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1002689","article-title":"Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.","volume":"363","author":"Pasternak","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi221425r7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10620-011-1940-3","article-title":"The safety of fetal exposure to proton-pump inhibitors during pregnancy.","volume":"57","author":"Matok","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"1","key":"zoi221425r9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/bdra.22865","article-title":"Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.","volume":"94","author":"Anderka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"7","key":"zoi221425r10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pds.3448","article-title":"Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007.","volume":"22","author":"Lind","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"zoi221425r11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/jnnp-2013-306941","article-title":"Risk factors for congenital hydrocephalus: a nationwide, register-based, cohort study.","volume":"85","author":"Munch","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"zoi221425r12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/apt.v51.4","article-title":"Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.","volume":"51","author":"Li","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"zoi221425r13"},{"issue":"8","key":"zoi221425r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi221425r15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the National Health Information database of the National Health Insurance Service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"zoi221425r16","doi-asserted-by":"publisher","author":"Noh","year":"2022","DOI":"10.1371\/journal.pmed.1003945"},{"issue":"10","key":"zoi221425r17","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.cgh.2020.09.054","article-title":"Familial risk of inflammatory bowel disease: a population-based cohort study in South Korea.","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"zoi221425r18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pds.3284","article-title":"Algorithms to estimate the beginning of pregnancy in administrative databases.","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi221425r20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","article-title":"Development of a comorbidity index for use in obstetric patients.","volume":"122","author":"Bateman","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"13","key":"zoi221425r21","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/bjo.2015.122.issue-13","article-title":"Validation of an obstetric comorbidity index in an external population.","volume":"122","author":"Metcalfe","year":"2015","journal-title":"BJOG"},{"issue":"6","key":"zoi221425r22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/EDE.0000000000000541","article-title":"Carryover effects in sibling comparison designs.","volume":"27","author":"Sj\u00f6lander","year":"2016","journal-title":"Epidemiology"},{"issue":"10","key":"zoi221425r23","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamainternmed.2021.4571","article-title":"Association between prenatal exposure to antipsychotics and attention-deficit\/hyperactivity disorder, autism spectrum disorder, preterm birth, and small for gestational age.","volume":"181","author":"Wang","year":"2021","journal-title":"JAMA Intern Med"},{"key":"zoi221425r25","doi-asserted-by":"publisher","author":"Desai","year":"2017","DOI":"10.1097\/EDE.0000000000000595"},{"issue":"7","key":"zoi221425r26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/ana.1989.44.issue-7","article-title":"Effect of single-dose omeprazole on intragastric acidity and volume during obstetric anaesthesia.","volume":"44","author":"Moore","year":"1989","journal-title":"Anaesthesia"},{"issue":"6","key":"zoi221425r29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"zoi221425r30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fphar.2012.00126","article-title":"Drug interactions at the human placenta: what is the evidence?","volume":"3","author":"Rubinchik-Stern","year":"2012","journal-title":"Front Pharmacol"},{"key":"zoi221425r31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fphys.2018.00406","article-title":"Amniotic fluid INSL3 measured during the critical time window in human pregnancy relates to cryptorchidism, hypospadias, and phthalate load: a large case-control study.","volume":"9","author":"Anand-Ivell","year":"2018","journal-title":"Front Physiol"},{"issue":"9","key":"zoi221425r32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/oem.2009.048272","article-title":"Parental occupational exposure to potential endocrine disrupting chemicals and risk of hypospadias in infants.","volume":"67","author":"Nassar","year":"2010","journal-title":"Occup Environ Med"},{"issue":"3","key":"zoi221425r33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1289\/ehp.1103998","article-title":"Identification of phthalates in medications and dietary supplement formulations in the United States and Canada.","volume":"120","author":"Kelley","year":"2012","journal-title":"Environ Health Perspect"},{"issue":"3","key":"zoi221425r34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/2042098613482484","article-title":"Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications.","volume":"4","author":"Heidelbaugh","year":"2013","journal-title":"Ther Adv Drug Saf"},{"issue":"22","key":"zoi221425r35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMe1009631","article-title":"Proton-pump inhibitors and birth defects\u2014some reassurance, but more needed.","volume":"363","author":"Mitchell","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi221425r36","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/bdra.v88.12","article-title":"Craniosynostosis and nutrient intake during pregnancy.","volume":"88","author":"Carmichael","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"zoi221425r39","first-page":"53","article-title":"Toxicological studies on omeprazole.","volume":"108","author":"Ekman","year":"1985","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"3","key":"zoi221425r40","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar4177","article-title":"The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.","volume":"15","author":"Scheiman","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"zoi221425r41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0b013e31825fa230","article-title":"Sibling comparison designs: bias from non-shared confounders and measurement error.","volume":"23","author":"Frisell","year":"2012","journal-title":"Epidemiology"},{"issue":"5","key":"zoi221425r42","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/aje\/kwaa183","article-title":"Invited commentary: sibling-comparison designs, are they worth the effort?","volume":"190","author":"Frisell","year":"2021","journal-title":"Am J Epidemiol"},{"key":"zoi221425r28","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/B978-0-12-804239-7.00067-6","volume-title":"Reproductive and Developmental Toxicology","author":"Karttunen","year":"2017"},{"key":"zoi221425r8","doi-asserted-by":"crossref","unstructured":"Rhim? AD, Hardy JR, Haynes K, Testani JM, Yang YX. Maternal use of proton pump inhibitors (PPI) during pregnancy is associated with an increased risk for cardiac birth defects: analysis of 208,951 pregnancies from the GPRD\/THIN database. Abstract 475b. AGA Abstracts; 2010:S-63. Accessed October 1, 2021. https:\/\/www.academia.edu\/23321167\/475b_Maternal_use_of_Proton_Pump_Inhibitors_PPI_During_Pregnancy_is_Associated_With_an_Increased_Risk_for_Cardiac_Birth_Defects_Analysis_of_208_951_Pregnancies_From_the_GPRD_THIN_Database","DOI":"10.1016\/S0016-5085(10)60285-5"},{"key":"zoi221425r19","unstructured":"European Commission. EUROCAT: European network of population-based registries for the epidemiological surveillance of congenital anomalies. European Commission; 2020. Accessed November 9, 2021. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat"},{"key":"zoi221425r24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology. Updated December 8, 2021. Accessed Month November 15, 2021. https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/guidelines"},{"key":"zoi221425r27","unstructured":"van Leeuwen? L. Proton Pump Inhibitors During Pregnancy and Adverse Pregnancy Outcomes. Master\u2019s thesis. Rijksuniversiteit Groningen; 2019. https:\/\/fse.studenttheses.ub.rug.nl\/19436"},{"key":"zoi221425r37","unstructured":"Prilosec (omeprazole). Prescribing information. AstraZeneca Pharmaceuticals; 2012. Accessed March 31, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019810s096lbl.pdf"},{"key":"zoi221425r38","unstructured":"Prevacid (lansoprazole). Prescribing information. Takeda Pharmaceuticals America; 2012. Accessed March 31, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020406s078-021428s025lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800163\/choi_2023_oi_221425_1672242308.05477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T11:08:09Z","timestamp":1673348889000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50366","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}